检索结果-南通市图书馆

Transcellular transport characteristics of huperzine alone or in combination with ginkgolide B across Caco-2 and Madin-Darby canine kidney cell mono.ayer

在线全文

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Medicine 2014年第11期7卷 889-894页

作者： Wen-Cui Zhao Zhi-Hong Hou Qi Zhang Wei Zheng Pharmacy Department 208th Hospital of PLA. hospital Office 208th Hospital of PLA. Infirmary 208th Hospital of PLA.

Objective:To study the various processes involved in transcellular transport(TT) of huperzine A alone or in combination with ginkgolide B in Caco-2 and Madin-Darby canine renal(MDCK)cell ***:The transepithelial passage was assayed in the apical-to-basolateral(AP to BL) direction and opposite direction(BL to AP) in both cell *** determination of huperzine A and ginkgolide B were performed by high performance liquid chromatography(HPLC).The passage rates of huperzine A and ginkgolide B were ***-directional TT(absorption and secretion) were taken in huperzine A and ginkgolide B in Caco-2 and MDCK cell ***:TT absorption and secretion kinetics of huperzine A and ginkgolide B across two cells existed at the same *** passage rates of huperzine A were increased significantly with adding different concentrations of ginkgolide ***:The compound preparations of HA in combination with CB for dementia caused by cerebral ischemic have synergistic effects on the pharmacodynamics,and improve the bioavailability through BBB.

关键词： Caco-2 Huperzine A Ginkgohde B Madin-Darby canine renal Transcellular Transport

Expression of hENT1 and ERCC1 genes in tumor tissues no.-small cell lung cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Medicine 2013年第11期6卷 908-911页

作者： Jia-Jia Wu Shun-Chang Jiao Department of Training PLA General Hospital Department of Medical Oncology PLA General Hospital

Objective:To investigate the expression of hENT1 and ERCCl genes in tumor tissues no.-small cell lung cancer(NSCLC).Methods:Fresh no.-small lung cancer specimens were transplanted into nude *** mice were randomized into two groups:experimental group receiving gemeitabine plus cisplatin and control group receiving 0.9%physiological *** expressions of hENTi and ERCC1 mRNA in tumor tissue were detccted by real-time fluorescent quantitative *** volume of tumor,the weight of nude mice and tumor volume were respectively measured and calculated 2-3 times per *** samples were collected from NSCLC mice treated with gemeitabine plus ***:The histological examination showed that many tumor cells were well preserved in nude *** rate of transplanted tumor cells was 86.7%.The concomitant treatment study showed that the rate of TV,RTV,T/C in GEM + DDP group was the *** + DOC,DDP + DOC obviously influenced the body *** with NS group,DDP group,GEM group,the survival period and the level of hENTl of DDP+GEM group increased obviously,the level of ERCC1 decreased significantly(Pno.is of patients with NSCLC treated with gemeitabine plus cisplatin.

关键词： hENT1 ERCC1 no.-small cell lung cancer Chemotherapy Gemcitabine

An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T(CAR-T) cells

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2016年第4期59卷 379-385页

作者： Yajing Zhang Wenying Zhang Hanren Dai Yao Wang Fengxia Shi Chunmeng Wang Yelei Guo Yang Liu Meixia Chen Kaichao Feng Yan Zhang Chuanjie Liu Qingming Yang Suxia Li Weidong Han Bio-therapeutic Department Chinese PLA General Hospital Molecular & Immuno.ogical Department Institute of Basic Medicine School of Life Sciences Chinese PLA General Hospital Department of Geriatric Hematology Chinese PLA General Hospital State key laboratory of kidney disease Chinese PLA General Hospital

Anti-CD19 chimeric antigen receptor-modified T(CAR-T-19) cells have emerged as a powerful targeted immuno.herapy for B-cell lineage acute lymphoblastic leukemia with a remarkable clinical response in recent trials. no.etheless, few data are available on the subsequent clinical monitoring and treatment of the patients, especially those with disease recurrence after CAR-T-19 cell infusion. Here, we analyzed three patients who survived after our phase I clinical trial and who were studied by means of biomarkers reflecting persistence of CAR-T-19 cells in vivo and predictive factors directing further treatment. One patient achieved 9-week sustained complete remission and subsequently received an allogeneic hematopoietic stem cell transplant. Ano.her patient who showed relapse after 20 weeks without detectable leukemia in the cerebrospinal fluid after CAR-T-19 cell treatment was able to achieve a morphological remission under the influence of stand-alone low-dose chemotherapeutic agents. The third patient gradually developed extensive extramedullary involvement in tissues with scarce immune-cell infiltration during a long period of hematopoietic remission after CAR-T-19 cell therapy. Long-term and discontinuous increases in serum cytokines(mainly interleukin 6 and C-reactive protein) were identified in two patients(no.. 1 and 6) even though only a low copy number of CAR molecules could be detected in their peripheral blood. This finding was suggestive of persistent functional activity of CAR-T-19 cells. Combined analyses of laboratory biomarkers with their clinical manifestations before and after salvage treatment showed that the persistent immuno.urveillance mediated by CAR-T-19 cells would inevitably potentiate the leukemia-killing effectiveness of subsequent chemotherapy in patients who showed relapse after CAR-T-19-induced remission.

关键词： chimeric antigen receptor T cells B-cell acute lymphoblastic leukemia biomarker immuno.urveillance microenvironment

Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent resteno.is: an updated meta-analysis of randomized studies

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2019年第6期16卷 448-457页

作者： Lei GAO Ya-Bin WANG Jing JING Ming ZHANG Yun-Dai CHEN Department of Cardiology Chinese PLA General Hospital

Background New-generation drug-eluting stents (DES) was more effective in the treatment of in-stent resteno.is (ISR) compared with the first-generation DES. Drug-eluting balloons (DEB) and new-generation DES had been available strategies in treatment of bare-metal stents/DES ISR (BMS/DES-ISR). Six new randomized trials have recently examined the angiographic outcomes and one-year clinical outcomes of DEB and new generation DES in BMS/DES-ISR. However, the optimal management for BMS/DES-ISR lesions remains controversial. Methods We searched the randomized clinical trials evaluating the angiographic outcomes and one-year clinical outcomes of DEB and new-generation DES in patients with BMS/DES-ISR. The primary endpoints were the angiographic outcomes, including the minimal luminal diameter (MLD), diameter steno.is %(DS%), late lumen loss (LLL), and binary resteno.is (BR). Results A total of six randomized clinical trials with 1177 BMS/DES-ISR patients were included in our meta-analysis. For angiographic outcomes, there were significantly less MLD and more DS% with DEB compared to new-generation DES (MLD: MD =?0.18, 95% CI:?0.31– ?0.04, P < 0.001;DS%: MD = 5.68, 95% CI: 1.00–10.37, P < 0.001). Moreover, for one-year clinical outcomes, DEB was associated with a significant increase risk in target lesion revascularization (TLR)(RR = 2.93, 95% CI: 1.50–5.72, P = 0.002). However, DEB was associated with higher risks of major adverse cardiac event, target vessel revascularization, TLR, BR, and more DS% only in DES-ISR group. Conclusions DEB and new-generation DES have the similar clinical efficacy for the treatment of BMS-ISR. However, DES showed more MLD, less DS%, and a decreased risk of TLR for the treatment of DES-ISR.

关键词： Drug-eluting balloons Drug-eluting stents In-stent resteno.is Meta-analysis

Combination therapy reduces the incidence of no.reflow after primary percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2015年第02期12卷 135-142页

作者： Shan-Shan ZHOU Feng TIAN Yun-Dai CHEN Jing WANG Zhi-Jun SUN Jun GUO Qin-Hua JIN Department of Cardiology Chinese PLA General Hospital

Background no.reflow is associated with an adverse outcome and higher mortality in patients with ST-segment elevation acute myocardial infarction(STEMI) who undergo percutaneous coronary intervention(PCI) and is considered a dynamic process characterized by multiple pathogenetic *** aim of this study was to investigate the effectiveness of a combination therapy for the prevention of no.reflow in patient with acute myocardial infarction(AMI) undergoing primary *** A total of 621 patients with STEMI who underwent emergency primary PCI were enrolled in this *** with high risk of no.reflow(no.flow score > 10,by using a no.flow risk prediction model,n = 216) were randomly divided into a controlled group(n = 108) and a combination therapy group(n = 108).Patients in the controlled group received conventional treatment,while patients in combination therapy group received high-dose(80 mg) atorvastatin pre-treatment,mtracoronary administration of adeno.ine(140 μg/min per kilogram) during PCI procedure,platelet membrane glycoproteinⅡb/Ⅲa receptor antagonist(tirofiban,10μg/kg bolus followed by 0.15 μg/kg per minute) and thrombus *** contrast echocardiography was performed to assess the myocardial perfusion 72 h after *** adverse cardiac events(MACE) were followed up for six *** Incidence of no.reflow in combination therapy group was 2.8%,which was similar to that in low risk group 2.7%and was significantly lower than that in control group(35.2%,P no.-fatal MIs and three revascularizations) in combination therapy group and 12(13.2%)(four deaths,three no.-fatal MIs and five revascularizations,P < 0.05) in control *** Combination of thrombus aspiration,high-dose statin pre-treatment,intracoronary administration of a

关键词： Acute myocardial infarction Myocardial contrast echocardiography no.reflow pheno.eno. Percutaneous coronary intervention ST-elevation myocardial infarction

Application of human bone marrow-derived mesenchymal stem cells in the treatment of radiation-induced gastrointestinal syndrome

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2014年第12期57卷 1177-1182页

作者： YANG Chao DAI Wei Min CHEN Hai Xu WU Ben Yan Gastrointestinal Department of Southern Building General Hospital of Chinese PLA Department of Thoracic Surgery General Hospital of Chinese PLA Institute of Gerontology and Geriatrics General Hospital of Chinese PLA

Nuclear accidents and terrorism present a serious threat for mass *** or intended radiation exposure leads to radiation-induced gastrointestinal(GI)***,currently there are no.approved medical countermeasures for GI ***,developing no.el treatments for GI syndrome is *** stem cells(MSCs)derived from bone marrow are a subset of multipotent adult somatic stem cells that have the ability to undergo self-renewal,proliferation and pluripotent *** have advantages over other stem cells;they can be easily isolated from patients or dono.s,readily expanded ex vivo,and they possess reparative and immuno.odulatory ***,MSCs have been shown to be powerful tools in gene therapy and can be effectively transduced with vectors containing therapeutic ***,the therapeutic potential of MSCs has been brought into the spotlight for the clinical treatment of GI *** this review,we discuss the possible role of MSCs in radiation-induced GI syndrome.

关键词： mesenchymal stem cells radiation-induced gastrointestinal syndrome treatment

Primary hepatic neuroendocrine tumor case with a preoperative course of 26 years: A case report and literature review

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2018年第24期24卷 2640-2646页

作者： Xiang-Fei Meng Ying-Wei Pan Zhan-Bo Wang Wei-Dong Duan Department of Hepatobiliary Surgery Chinese PLA General Hospital Department of Pathology Chinese PLA General Hospital

Primary hepatic neuroendocrine tumor(PHNET) is an extremely rare liver tumor. Patients often have no.clinical symptoms or have only no.-specific symptoms, such as abdominal pain and abdominal mass. The clinical manifestations, disease development, treatment methods, and treatment outcomes of PHNET vary greatly among cases. Here we report a case of PHNET with a confirmed 26-year survival before surgery. The patient was a 56-year-old female. A large right hepatic mass was detected when the patient was 30 years old. The tumor could no. be removed during exploratory laparotomy, and constriction of the right hepatic artery and biopsy were conducted. Pathological results indicated a diagno.is of benign tumor, but a confirmed diagno.is was no. reached. Twenty-six years after the patient had been living with the tumor, she sought treatment again because of tumor progression. After systematic evaluation of the resectability, the tumor was resected. Based on the examination results of the gastrointestinal tract and lungs, intraoperative examination results, pathological findings, and long-term follow-up results, the diagno.is of PHNET was confirmed. This case represents the longest reported survival time for a PHNET patient before removal of the tumor.

关键词： Primary hepatic neuroendocrine tumor Surgery Pathology Radiology Surgical plan Follow up

Chinese expert consensus on the clinical application of drugcoated balloon(2^(nd) Edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第2期21卷 135-152页

作者： The Expert Writing Committee of the Chinese Expert Consensus on Clinical Applications of Drug-Coated Balloon(2^(nd)Edition) Jun-Bo GE Yun-Dai CHEN 不详 Zhongshan hospital Fudan University Chinese pla General hospital

Percutaneous coronary interventions have progressed through the era of plain balloon dilation, bare-metal stent insertion to drug-eluting stent treatment, which has significantly reduced the acute occlusion and resteno.is rates of target vessels and improved patient progno.is, making drug-eluting stents the mainstream interventional treatment for coronary artery disease. In recent years, drug-coated balloons(DCBs) have become a new treatment strategy for coronary artery disease, and the drugs used in the coating and the coating techno.ogy have progressed in the past years. Without permanent implant, a DCB delivers antiproliferative drugs rapidly and uniformly into the vessel wall via the excipient during a single balloon dilation. Many evidence suggests that DCB angioplasty is an effective measure for dealing with in-stent resteno.is and de no.o lesions in small coronary *** more clinical studies are published, new evidence is emerging for the use of DCB angioplasty in a wide range of coronary diseases, and the indications are expanding internationally. Based on the latest research from China and elsewhere, the Expert Writing Committee of the Chinese Expert Consensus on Clinical Applications of Drug-Coated Balloon has updated the previous DCB consensus after evidence-based discussions and meetings in terms of adequate preparation of in-stent resteno.is lesions, expansion of the indications for coronary de no.o lesions, and precise guidance of DCB treatment by intravascular imaging and functional evaluation.

关键词： balloon drugs dealing

Advances in Journal of Geriatric Cardiology over the course of a decade

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2020年第12期17卷 733-739页

作者： Qiang WU Lai-Fu LI Yun-Dai CHEN Institute of Geriatric Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Journal of Geriatric Cardiology Editorial Office Chinese PLA General HospitalBeijingChina

The Journal of Geriatric Cardiology(JGC,ISSN 1671-5141/CN 11-5329/R)is a monthly,open-access,international,and peer-reviewed journal sponsored and published by the Institute of Geriatric Cardiology affiliated with Chinese pla General *** was created in 2004 by ***-Wen WANG,and as the current editor-in-chief,***-Dai CHEN has been involved in JGC for eight years and has achieved impressive advancements.

关键词： Bibliometrics Citation analysis Journal of Geriatric Cardiology Peer review Research hotspots